| INTRODUCTION
Estimates from the World Health Organization (WHO) show that, in 2015, the global prevalence of depression increased with age, reaching a peak at around 60 years. 1 Beyond 60 years, in the elderly population (65-79 years), the prevalence of depression remained at high levels. 1 Depression in the elderly is associated with considerable burden, by exacerbating other illnesses, and increasing mortality. 2 Many older adults with major depressive disorder (MDD) fail to achieve an adequate response to antidepressant treatment (ADT). 3 Adjunctive treatment with atypical antipsychotics has been shown to enhance the response to ADT in clinical trials of adults (18-65 years; mean age of approximately 45 years). 4 However, evidence that adjunctive antipsychotics may enhance antidepressant response in elderly populations (≥65 years) is limited. Aripiprazole is the only adjunctive antipsychotic with evidence of efficacy versus placebo in patients aged ≥60 years with inadequate response to ADT (and also in patients aged 50-67 years in a post hoc study). 5, 6 Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at serotonin 5-HT 1A and dopamine D 2 receptors and as an antagonist at serotonin 5-HT 2A and noradrenaline α 1B/ 2C receptors, all with subnanomolar potency. 7 The efficacy and safety of brexpiprazole as adjunctive treatment to ADT over 6 weeks has been demonstrated in 4 studies in adult patients (aged 18-65 years)
with MDD. [8] [9] [10] [11] Brexpiprazole is approved in the USA as an adjunctive therapy to antidepressants for the treatment of adults with MDD, and in the USA, Canada, Australia, and Japan as monotherapy for the treatment of adults with schizophrenia.
The use of adjunctive antipsychotic treatment for depression has been limited because of safety concerns in relation to antipsychotics (eg, weight gain, metabolic effects, extrapyramidal symptoms [EPS], sedation, and akathisia). 12 Potential cardiovascular risks are particularly relevant to an elderly population. 13 The objective of this study (Aquila) was to evaluate the long-term safety and tolerability of flexible-dose brexpiprazole as adjunctive treatment to ADT in elderly patients with MDD and an inadequate response to prior ADT.
2 | METHODS
| Patients
The Aquila study (ClinicalTrials.gov identifier: NCT02400346) was conducted in accordance with the International Conference on
Harmonisation Good Clinical Practice Guideline, and with the principles laid out in the Declaration of Helsinki (1964, plus amendments).
The study protocol was approved by the relevant institutional review boards and independent ethics committees. All patients provided written informed consent prior to enrolling in the study. Following screening, eligible patients received brexpiprazole as adjunctive treatment to their current ADT (the ADT that they were receiving prior to screening) during a 26-week treatment period.
Brexpiprazole was titrated from 0.5 mg/day to 2 mg/day over the first
Key points
• The use of adjunctive antipsychotics to enhance antidepressant response in depressed elderly populations is hindered by safety concerns and limited evidence of efficacy.
• The present study evaluated the long-term safety of flexibly dosed brexpiprazole adjunct to antidepressant treatment in elderly patients with major depressive disorder.
• No new safety or tolerability concerns were noted with adjunctive brexpiprazole in the elderly compared to previous studies in adults aged 18-65 years.
• Improvements were observed in depressive symptoms, social functioning, and quality of life, suggesting that brexpiprazole may be useful to treat depression in the elderly.
4 weeks (first week, 0.5 mg/day; second week, 1 mg/day; third and fourth weeks, 2 mg/day); thereafter, patients received adjunctive brexpiprazole at a dose of 1 to 3 mg/day, depending on clinical judgment and tolerability. Investigators were instructed not to change the dose of ADT during the study.
After study completion or withdrawal, patients entered a 4-week safety follow-up period, during which they stopped brexpiprazole treatment, but continued to receive their same ADT.
| Outcome measures
The primary objective of this study was to evaluate the long-term safety ). The mSAS is a 10-item scale used to measure drug-induced parkinsonism and EPS; the total score, obtained by taking the mean of the rated items, ranges from 0 (absence) to 4 (most extreme). 19, 20 The BARS Global clinical assessment item measures drug-induced akathisia on a scale from 0 (absent) to 5 (severe akathisia). 21 The AIMS is a 12-item scale used to assess dyskinetic movements of the face, trunk, and extremities among patients receiving antipsychotic drugs; the total score ranges from 0 (none) to 42 (most severe).
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Exploratory efficacy outcomes assessed the effect of brexpiprazole 1 to 3 mg/day as adjunct to ADT on depressive symptoms, using the clinician-rated MADRS; global illness severity and change, using the clinician-rated CGI-S and Clinical Global Impressions-Improvement (CGI-I) 17 ; social functioning, using the Social Adaptation Self-Evaluation Scale (SASS) 23 ; health-related quality of life, using the Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF) 24, 25 ; and well-being, using the EuroQoL 5
Dimensions 5 Levels (EQ-5D-5L) Health state score. 26 The SASS is a 21-item, patient-rated scale to assess social functioning in patients with depression; the total score ranges from 0 to 60, with higher scores indicating better functioning. 23 The Q-LES-Q-SF is a 16-item, patientrated measure of the degree of enjoyment and satisfaction experienced by patients in daily life; the total score of items 1 to 14 ranges from 14 (very poor) to 70 (very good); in addition, 2 global items ("medication"
and "life satisfaction and contentment") are each rated from 1 (very poor) to 5 (very good). 24, 25 The EQ-5D-5L Health state score is obtained from a patient-completed visual analog scale for overall health state, ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). 26 Safety and efficacy assessments were conducted at intervals of 1 to 6 weeks throughout the study.
| Data analysis
No formal sample size calculation was performed for this study. A total of 130 patients were planned to receive adjunctive brexpiprazole treatment. This sample size was considered to be suitable for observing potential new safety and tolerability signals for adjunctive brexpiprazole in elderly patients.
Safety and tolerability analyses were performed in the safety population, defined as all patients who received ≥1 dose of brexpiprazole.
Analyses comprised the incidence of treatment-emergent adverse events (TEAEs); the change from screening or baseline in movement disorder scales, standard safety assessments, and MMSE score; and the incidence of suicidality based on the C-SSRS. Descriptive statistics are presented for safety and tolerability outcomes. reduction from baseline in MADRS total score and a MADRS total score ≤10) were calculated for the LOCF dataset.
3 | RESULTS
| Patients
Patient disposition is presented in Figure 1 . A total of 132 patients were enrolled and treated, of whom 88 (66.7%) completed 26 weeks duloxetine, n = 13 (9.8%); venlafaxine immediate/extended release (IR/XR), n = 13 (9.8%); mirtazapine, n = 12 (9.1%); paroxetine immediate/controlled release (IR/CR), n = 7 (5.3%); bupropion, n = 3 (2.3%); desvenlafaxine, n = 1 (0.8%); and vilazodone, n = 1 (0.8%).
The mean (SD) of each patient's mean and modal doses of brexpiprazole across the entire study was 1.8 (0.6) mg and 1.9 (0.7) mg, respectively.
| Safety and tolerability
Overall, 102 patients (77.3%) experienced at least 1 TEAE. Of these patients, 25 (18.9%) had only mild TEAEs, 66 (50.0%) had at least 1 moderate TEAE (but no severe TEAEs), and 11 (8.3%) had at least 1 severe TEAE. Fatigue and restlessness were the 2 most frequently reported TEAEs, and the only TEAEs with incidence ≥10% (Table 2) .
Overall, 25 patients (18.9%) discontinued the study because of TEAEs, the most frequent of which were fatigue (n = 4; 3.0%), akathisia, tremor (both n = 3; 2.3%), anxiety, and depression (both n = 2; 1.5%). No patients died during the 26-week open-label treatment period. One death (because of myocardial infarction and myocardial rupture) occurred during the safety follow-up phase, which was considered by the investigator to be unrelated to adjunctive brexpiprazole.
A total of 4 patients (3.0%) experienced a TEAE of fall during treatment with adjunctive brexpiprazole, which was reported as a all n = 96).
Weight increase was reported as a TEAE in 11 patients (8.3%) ( Table 2) . One patient (0.8%) who had a history of hypothyroidism experienced a TEAE of increased body weight that resulted in treatment discontinuation. Mean (SD) change in body weight from baseline was 0.9 (3.6) kg at week 26 (n = 89). A total of 16 patients (12.3%) had a ≥7% weight increase from baseline, whereas 4 patients (3.1%) had a ≥7% weight decrease from baseline. Aside from mild increases in mean prolactin level, there were no consistent clinically relevant findings observed with regard to laboratory measurements (including glucose, cholesterol, and triglycerides) ( Table 3) , or vital signs. The mean change from baseline in QT c interval on ECG readings was small, and not considered to be clinically relevant.
The mean (SD) change in MMSE total score from baseline to last postbaseline assessment was −0.2 (1.6) points (n = 119).
One patient without suicidal ideation at baseline experienced treatment-emergent suicidal ideation (C-SSRS score of 1). There were no instances of suicidal ideation with intent or a plan (score of 4 or 5), no instances of suicidal behavior (score of 6-10), and no reports of suicide-related TEAEs.
| Efficacy
On the MADRS total score, patients' depressive symptoms improved on average over 26 weeks of brexpiprazole treatment (Figure 2A ).
The mean (SE) change from baseline in MADRS total score at week 26 was −14.5 (0.9) points (MMRM; Table 4 ). Most of the improvement in MADRS total score occurred during the first 14 weeks of adjunctive brexpiprazole treatment, although improvement continued to the end of the 26-week treatment period.
Other exploratory efficacy endpoints for depressive symptoms are presented in Table 4 . Patients showed global improvement over 26 weeks, as measured by the CGI-S and CGI-I. Considering adjunctive aripiprazole, a 12-week randomized, doubleblind study in 181 elderly patients (≥60 years) with inadequate response to ADT had a high incidence of akathisia, which was reported by 26.4%
of patients receiving aripiprazole, compared with 12.2% in the placebo group. 5 Thus, in elderly patients with depression, quetiapine shows a propensity for sedating side effects, whereas aripiprazole shows a pro- with MDD. 31 As expected, mild prolactin elevations were observed in the present study, but were not associated with TEAEs. The proportion of patients with prolactin levels >2× the upper limit of normal was also low and consistent with the previous long-term studies of brexpiprazole in adult patients (18-65 years) with MDD.
weight increased by an average of 0.9 kg over 26 weeks in the present study, with most of the gain occurring in the first 3 months of brexpiprazole treatment. The incidence of ≥7% weight increase from baseline was lower than reported in the other long-term brexpiprazole studies (although the previous studies were 52 weeks in duration). 31 There was no indication that the weight gain observed in the present study was associated with clinically meaningful changes in metabolic parameters, which is consistent with the findings of other studies in the brexpiprazole clinical development program. In the randomized, double-blind study of adjunctive aripiprazole in elderly patients, it is notable that, while modest weight gain was observed over 12 weeks (1.9 kg on average), only about 30% was because of body fat gain. 
